Lyme retreatment guidance may be flawed

Accepted medical practice discourages antibiotic retreatment in cases where Lyme disease symptoms persist. A new review of studies behind current medical advice says those studies prove nothing. Credit: Centers for Disease Control

(Medical Xpress)—Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.

Allison DeLong, a at Brown University's Center for and lead author of the study published online Aug. 19, 2012, in Contemporary , said the four studies do not prove that retreatment does not work. That questionable interpretation, however, has led doctors to forgo treatment and to withhold reimbursement.

"The goal of the paper is to clarify what was actually found from these clinical trials and what could be said and what couldn't be said," DeLong said. "A lack of evidence should not be used to deny treatment when the studies have serious flaws."

Evidence in the trials is most often inconclusive, she and three co-authors found. Two studies even found some statistically significant benefits from antibiotics.

DeLong has been curious about Lyme disease retreatment for more than a decade since a friend of hers seemed to benefit from therapy. Her friend paid for the treatment out-of-pocket. would call that anecdote an "n of 1," but the example stuck with DeLong as more people, including journalists, began to question whether retreatment really was ineffective.

In 2009 and 2010, DeLong and her colleagues decided to look into the matter with full statistical rigor. Their analysis started by scanning the for any randomized clinical trials offering evidence of the efficacy of antibiotic retreatment for Lyme disease. Careful review of more than 100 studies ultimately whittled the field down to the four studies on which the Infectious Diseases Society of America and the American Academy of Neurology are based their guidelines.

The most influential studies were conducted by Klempner et al., and published together in the New England Journal of Medicine in 2001. The multicenter trials enrolled chronic Lyme sufferers with positive or negative blood serum results for Immunoglobulin G, an antibody that might indicate active infection. In each of the IgG positive and negative groups, patients either received IV antibiotics followed by oral antibiotics or IV placebo followed by oral placebo. Their symptoms were measured along the way using a subjective set of health quality-of-life measures called the SF-36.

Although Klempner et al. found no significant benefit to retreatment, findings from subsequent SF-36 studies in chronic illnesses provide evidence that the Klempner study was looking for unrealistically large differences.

"The trials, as designed, called for treatment effects considerably larger than the minimum clinically important differences (MCID) identified in other chronic illnesses, suggesting that the sample sizes were inadequate and the trials were very likely underpowered to detect the true underlying MCIDs," DeLong and her co-authors wrote in the journal.

Klempner's statistics showed that treatment might or might not have been effective given the broad range of a statistical measure known as the confidence interval, DeLong said.

In another of the four trials conducted by Krupp et al., researchers found that retreatment produced a significant benefit for fatigue, but the authors of the study mistakenly discounted that result, DeLong said.

The authors became concerned that their results were tainted by too many subjects realizing that they were receiving real treatment instead of the placebo. The measure of fatigue is subjective and could be influenced by that realization. But DeLong found that the subjects weren't likely to have realized anything. Here's why: If the members of each group have a blindly optimistic seven in 10 chance of believing that they received real medicine, then the people who really were would be right seven out of 10 times and the people receiving the placebo would only be right 3 out of 10 times. The people receiving the medicine would seem like they had discovered their status, but in reality they were only making a lucky, optimistic guess.

While the Krupp study was adequately powered to measure a significant benefit from fatigue, it had less power to measure the two other treatment effects it considered: improvements in cognitive processing and clearance of a potential Lyme disease biomarker, DeLong said.

The last of the four studies, by Fallon et al., had a very small sample size. It found hints of some benefits from retreatment but nothing definitive either positively or negatively.

Ultimately, DeLong said, the best evidence to support or refute antibiotic retreatment will come when scientists develop a definitive test for active Lyme disease infection. In the interim, it is possible that chronic patients harbor an ongoing infection that could treat.

"The interpretation of the trials goes too far," she said. "You can't say it's been shown that retreatment is not beneficial. You can't then jump to the conclusion that this shows there is no persistence of infection."

add to favorites email to friend print save as pdf

Related Stories

Chronic Lyme disease: How often is it diagnosed and treated?

Sep 02, 2010

The existence of chronic Lyme disease is an issue of sharp debate within the medical community. Some health care workers who call themselves "Lyme literate" insist that chronic Lyme disease is frequently diagnosed and treated ...

Panel upholds controversial Lyme disease guidelines

Apr 23, 2010

Recommendations released Thursday on how to treat Lyme disease are likely to fuel an ongoing debate on whether the disease is chronic and whether it's appropriate to prescribe long-term antibiotics to combat the infection.

Standard retreatment regimen for TB is inadequate

Mar 15, 2011

The standard retreatment regimen for tuberculosis has low treatment response rates and is associated with poor long term outcomes in certain subgroups of patients, particularly those infected with both HIV and multi-drug ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

21 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

21 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

Apr 19, 2014

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments